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lization (p < 0.01). An increase in the EuroQol score by 10%
was signiﬁcantly associated with decrease in annual health care
costs by 4.5% (p < 0.05). Each diabetes drug reﬁll was signiﬁ-
cantly associated with increase in the average health care costs
by 3.7% (p < 0.001), while each diabetes related inpatient visit
was associated with a 117% increase in average health care costs
(p < 0.001). CONCLUSIONS: This study showed signiﬁcant
associations between diabetes related utilization, health status
and diabetes medication adherence. Medication utilization was
further signiﬁcantly associated with health care costs. The study
ﬁndings highlight the need for maintaining improved health
status, and promoting cost-effective drug therapy in Type-2 
diabetes.
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and antidiabetic medication use in Germany. METHODS: Data
for this study were obtained from the German Disease Ana-
lyzer—Mediplus database. All patients who were identiﬁed with
type-2 diabetes between January 1, 2004 and December 31,
2004, were at least 20 years of age, and received at least one
HbA1c test between April 1, 2004 and December 31, 2004 were
included in the analysis (N = 5,135). Medication use was exam-
ined for the 90 days prior to the individual’s most recent HbA1c
test. RESULTS: Among those patients who were treated with
antidiabetic medication (61.93%), individuals were most com-
monly prescribed metformin monotherapy (33.55%), sulfony-
lurea monotherapy (18.18%), oral combination therapy
(17.68%), insulin monotherapy (16.92%), or insulin plus oral
therapy (7.13%). Over half of all patients diagnosed with type-
2 diabetes (52.74%) did not obtain a recommended range of
glycemic control of 6.5% or below. Comparing patients who
were within the recommended range of glycemic control to those
above the targeted range revealed no signiﬁcant differences in
mean age, sex, or comorbidities reported in 2004. In contrast,
there were signiﬁcant differences in the percentage of patients
who obtained the recommended range of glycemic control based
on antidiabetic medication prescribed (p < 0.0001). Patients
treated with insulin combination therapy or insulin monother-
apy were least likely to be within the targeted range of HbA1c
(22.91% and 26.58%, respectively), while only 31.85% of those
treated with oral combination therapy were within the targeted
range. CONCLUSIONS: Over half of patients diagnosed with
type-2 diabetes do not achieve the targeted range of glycemic
control. For a majority of patients, alternative therapy regimens
seem necessary to achieve good glycemic control.
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OBJECTIVE: In patients with type-2 diabetes (PwT2D) sufﬁ-
cient blood glucose control, also at an early stage, often cannot
be reached by using oral antidiabetic drugs (OAD) alone so that
the administration of insulin is necessary. Frequently, insulin
therapy is initiated too late, which is mostly due to the patients’
aversion to insulin. The aim of this survey was to investigate the
inﬂuence of knowledge about insulin and the willingness to start
using insulin treatment (WUI) in PwT2D on HbA1c not ade-
quately controlled on OAD alone. METHODS: Study materials
were sent out nation-wide to general practitioners by mail. The
patient questionnaire covered the following topics: WUI;
patients’ reported well-being; perceived seriousness of T2D; per-
ceived susceptibility to diabetic complications; expectations
regarding beneﬁcial and adverse effects of insulin; perceived
incompatibility with daily routine. A 10-point rating scale (1 =
totally disagree / 10 = totally agree) was used to document
patient assessments. The assessments were analyzed descrip-
tively. RESULTS: Out of 729 patients, 448 were treated with
OAD only. In total, 222 had low WUI (1–5 points = group1/G1);
217 had high WUI (6–10 points = group2/G2); not answered n
= 9. A high percentage of patients indicated that they were aware
of the seriousness of their T2D (G1 = 83%; G2 = 93% agree-
ment). Yet, the majority of the patients did not agree that they
had a severe stage of T2D (G1 = 79%; G2 = 73%). Patients with
lower WUI showed less knowledge regarding insulin. HbA1c
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OBJECTIVE: Given that control of blood glucose improves
long-term outcomes for patients diagnosed with type-2 diabetes,
the objective of this study is to examine levels of glycemic control
W
IT
HD
RA
W
N
